Holen Sie sich die Stockscreener-App
31.31
1.42%
-0.45
Vorhandelsmarkt:
31.76
0.45
+1.44%
Schlusskurs vom Vortag:
$31.76
Offen:
$32
24-Stunden-Volumen:
1.96M
Relative Volume:
0.74
Marktkapitalisierung:
$3.64B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-472.34M
KGV:
-7.552
EPS:
-4.1459
Netto-Cashflow:
$-340.33M
1W Leistung:
-3.33%
1M Leistung:
-10.03%
6M Leistung:
-14.15%
1J Leistung:
+6.17%
1-Tages-Spanne:
$30.46
$32.33
1-Wochen-Bereich:
$28.82
$32.42
52-Wochen-Spanne:
$22.96
$43.15
Viking Therapeutics Inc Stock (VKTX) Company Profile
Firmenname
Viking Therapeutics Inc
Sektor
Branche
Telefon
858-704-4660
Adresse
9920 PACIFIC HEIGHTS BLVD, SUITE 350, SAN DIEGO, CA
Compare VKTX vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
VKTX
Viking Therapeutics Inc
|
31.31 | 3.64B | 0 | -472.34M | -340.33M | -4.1459 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Viking Therapeutics Inc Stock (VKTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-26 | Eingeleitet | Wolfe Research | Peer Perform |
| 2025-10-29 | Eingeleitet | Canaccord Genuity | Buy |
| 2025-04-29 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2025-04-08 | Eingeleitet | Goldman | Neutral |
| 2025-02-13 | Eingeleitet | Scotiabank | Sector Outperform |
| 2025-02-07 | Eingeleitet | Citigroup | Neutral |
| 2024-12-02 | Eingeleitet | Piper Sandler | Overweight |
| 2024-11-22 | Eingeleitet | B. Riley Securities | Buy |
| 2024-11-04 | Bestätigt | H.C. Wainwright | Buy |
| 2024-09-11 | Eingeleitet | JP Morgan | Overweight |
| 2024-06-27 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-05-16 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2024-03-26 | Bestätigt | Oppenheimer | Outperform |
| 2024-03-07 | Eingeleitet | Jefferies | Buy |
| 2024-02-28 | Bestätigt | Oppenheimer | Outperform |
| 2023-05-31 | Fortgesetzt | ROTH MKM | Buy |
| 2023-03-28 | Bestätigt | Maxim Group | Buy |
| 2023-03-17 | Eingeleitet | Stifel | Buy |
| 2021-07-29 | Fortgesetzt | BTIG Research | Buy |
| 2021-05-25 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2020-06-05 | Eingeleitet | BMO Capital Markets | Outperform |
| 2020-05-05 | Eingeleitet | Chardan Capital Markets | Buy |
| 2020-05-01 | Eingeleitet | BTIG Research | Buy |
| 2019-07-16 | Eingeleitet | Oppenheimer | Outperform |
| 2019-06-25 | Eingeleitet | Stifel | Buy |
| 2019-03-29 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2019-03-14 | Bestätigt | Maxim Group | Buy |
| 2019-02-22 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2018-12-12 | Eingeleitet | B. Riley FBR | Buy |
| 2018-11-19 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2018-09-18 | Bestätigt | H.C. Wainwright | Buy |
| 2018-09-18 | Bestätigt | Maxim Group | Buy |
| 2018-09-18 | Bestätigt | Raymond James | Outperform |
| 2018-07-20 | Eingeleitet | SunTrust | Buy |
| 2018-06-28 | Eingeleitet | Raymond James | Outperform |
| 2018-06-01 | Bestätigt | Laidlaw | Buy |
| 2018-05-31 | Bestätigt | Maxim Group | Buy |
| 2018-03-26 | Fortgesetzt | H.C. Wainwright | Buy |
| 2017-11-28 | Bestätigt | Maxim Group | Buy |
| 2017-11-21 | Eingeleitet | ROTH Capital | Buy |
Alle ansehen
Viking Therapeutics Inc Aktie (VKTX) Neueste Nachrichten
VKTX Stock Slips Overnight: Investors Pin Hopes On Fresh Weight-Loss Data As Pfizer Joins Eli Lilly, Novo In GLP-1 War - Stocktwits
Obesity drug pill data and Phase 3 trial details head to ECO 2026 - Stock Titan
Viking Therapeutics: Market Betting On Big Upside Through 2030 (NASDAQ:VKTX) - Seeking Alpha
Viking Therapeutics Announces Two Poster Presentations at European Congress on Obesity (ECO) 2026 - ChartMill
Discipline and Rules-Based Execution in VKTX Response - Stock Traders Daily
VKTX Q1 earnings miss on higher phase 3 development costs - MSN
Dark Horse in the Weight-Loss Drug Arena? Viking Therapeutics Has Potential Upside of Over 200% - NAI500
Here's exactly why Wall Street thinks Viking Therapeutics stock could soar 207% over the next 12 months - MSN
Viking Therapeutics faces timeline risk, but upside could be huge - MSN
Here's Exactly Why Wall Street Thinks Viking Therapeutics Stock Could Soar 207% Over the Next 12 Months - The Motley Fool
Stock Market Today: Oil Jumps 5%, S&P 500 Drops As Iran Strikes UAE Port - Benzinga
CCORF Maintains Viking Therapeutics(VKTX.US) With Buy Rating, Maintains Target Price $107 - Moomoo
Viking Therapeutics Stock Surges on Bold Analyst Call - TipRanks
The $30 Stock Wall Street Values at $93? - Bitget
Viking Therapeutics: InvestingPro’s overvalued call proved prescient By Investing.com - Investing.com Australia
Viking Therapeutics, Inc. (VKTX) exceeds market returns: Some facts to consider - MSN
Why Viking Therapeutics (VKTX) Is Down 8.4% After Expanding VK2735 Phase 3 Obesity Program And Loss - Yahoo Finance
VKTX Shares Drop After Hours On Larger Q1 Losses But Retail Eyes The Launch Of Its Obesity Pipeline - Stocktwits
Viking Therapeutics, Inc. (VKTX) suffers a larger drop than the general market: Key insights - MSN
A New GLP-1 Challenger? Early Data Shows Viking's New Obesity Drug Tops Novo Rival - Stocktwits
VKTX Stock Outpaces LLY, ALT Ahead Of Earnings – Retail Eyes Breakout Ahead - Stocktwits
BTIG Maintains Viking Therapeutics(VKTX.US) With Buy Rating, Maintains Target Price $125 - Moomoo
A Look At Viking Therapeutics (VKTX) Valuation As Phase 3 Obesity Program Reaches Key Enrollment Milestones - simplywall.st
Viking Therapeutics (VKTX) Is Down 8.5% After Wider Q1 Loss And VANQUISH-2 Enrollment CompletionHas The Bull Case Changed? - Sahm
symbol__ Stock Quote Price and Forecast - CNN
Viking Therapeutics Stock (VKTX) Opinions on Q1 Earnings and Phase 3 Progress - Quiver Quantitative
Maxim Group Maintains Viking Therapeutics(VKTX.US) With Buy Rating, Maintains Target Price $70 - Moomoo
Viking Therapeutics Faces Timeline Risk—But Upside Could Be Huge - MarketBeat
Ligand tries to disembark from Viking pact, alleging breach - Fierce Biotech
Analysts Are Bullish on These Healthcare Stocks: Viking Therapeutics (VKTX), Regeneron (REGN) - The Globe and Mail
Viking Therapeutics, Inc. $VKTX Shares Sold by Pictet Asset Management Holding SA - MarketBeat
Viking Therapeutics, Inc. (VKTX) Outpaces Stock Market Gains: What You Should Know - MSN
VKTX SWOT Analysis: Financial Challenges and Promising Drug Pipe - GuruFocus
VKTX stock slips premarket: A surprise weight loss drug beats Novo Nordisk in early animal tests - MSN
Viking Therapeutics, Inc. Q1 2026 Financial Report: SEC 10-Q Filing, Financial Statements, and Key Disclosures - Minichart
Viking Therapeutics Q1 Viewed as Supporting Maintenance Profile, Oppenheimer Says - marketscreener.com
Vanguard holds 5.88M Viking Therapeutics shares (NASDAQ: VKTX) in 13G - Stock Titan
VKTX Q1 Earnings Miss on Higher Phase 3 Development Costs - The Globe and Mail
A Quick Look at Today's Ratings for Viking Therapeutics(VKTX.US), With a Forecast Between $71 to $125 - Moomoo
VKTX Maintains Overweight by Cantor Fitzgerald -- Price Target L - GuruFocus
Viking Therapeutics Q1 2026 Earnings Call Transcript - MarketBeat
Viking Therapeutics Earnings: Q3 Maintenance Study Data A Potential Wildcard (VKTX) - Seeking Alpha
Viking Therapeutics 1Q 2026: Revenue $0 Net loss $(158.3M), EPS $(1.37) — 10-Q Summary - TradingView
VKTX: Viking Therapeutics Inc Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
Viking Therapeutics (VKTX) Reports Progress in Obesity Drug Deve - GuruFocus
Viking Therapeutics Inc (VKTX) Q1 2026 Earnings Call Highlights: Strategic Advancements Amid Rising R&D Costs - GuruFocus
Viking outlines 52-week VANQUISH extension and plans oral VK2735 phase III start in Q4 2026 - MSN
VKTX stock draws fresh attention ahead of earnings: Wall Street sees over 170% upside as GLP-1 race burns hot - MSN
Viking Therapeutics rises after Q4 updates on obesity therapy - MSN
Viking Therapeutics Q1 Earnings Call Highlights - MarketBeat
Viking Therapeutics (VKTX) Maintains Strong Financial Position A - GuruFocus
Finanzdaten der Viking Therapeutics Inc-Aktie (VKTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.14%
0.48%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):